A simple assay system for infection-enhancing and -neutralizing antibodies to dengue type 2 virus using layers of semi-adherent K562 cells

Journal of Virological Methods

Volumn 163, Issue 2, 2010, Pages 360-367

  Konishi, Eiji ^a,b   Tabuchi, Yuko ^a   Yamanaka, Atsushi ^a,b,c  

^a KOBE UNIVERSITY   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c AIRLANGGA UNIVERSITY   (Indonesia)

Author keywords

ADE assay; Complement; Fc gamma receptor; Neutralization test

Indexed keywords

FC RECEPTOR; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; POLYLYSINE; VIRUS ANTIBODY;

ANTIBODY DEPENDENT ENHANCEMENT; ARTICLE; BLOOD SAMPLING; DENGUE VIRUS; ERYTHROLEUKEMIA CELL; HUMAN; IMMUNOHISTOCHEMISTRY; INCUBATION TEMPERATURE; NONHUMAN; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; SUSPENSION CELL CULTURE; VERO CELL; VIRUS CULTURE; VIRUS NEUTRALIZATION;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT ENHANCEMENT; DENGUE; DENGUE VIRUS; HUMANS; IMMUNOASSAY; K562 CELLS; NEUTRALIZATION TESTS; SENSITIVITY AND SPECIFICITY;

DENGUE VIRUS;

EID: 73049104008     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2009.10.026     Document Type: Article

References (29)

1. Bokisch V.A., Top Jr. F.H., Russell P.K., Dixon F.J., and Muller-Eberhard H.J. The potential pathogenic role of complement in dengue hemorrhagic shock syndrome. N. Engl. J. Med. 289 (1973) 996-1000
2. Green S., and Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr. Opin. Infect. Dis. 19 (2006) 429-436
3. Gubler D.J., Kuno G., and Markoff L. Flaviviruses. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology. 5th ed. (2007), Lippincott Williams & Willkins Inc., Philadelphia 1153-1252
4. Halstead S.B., and O'Rourke E.J. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 265 (1977) 739-741
5. Halstead S.B., and O'Rourke E.J. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J. Exp. Med. 146 (1977) 201-217
6. Halstead S.B., and O'Rourke E.J. Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting in vitro infection. J. Exp. Med. 146 (1977) 218-229
7. Halstead S.B. Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus Res. 60 (2003) 421-467
8. Halstead S.B. Dengue. Lancet 370 (2007) 1644-1652
9. Hatch S., Mathew A., and Rothman A. Dengue vaccine: opportunities and challenges. IDrugs 11 (2008) 42-45
10. Hombach J., Cardosa M.L., Sabchareon A., Vaughn D.W., and Barrett A.D. Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005. Vaccine 25 (2007) 4130-4139
11. Huisman W., Martina B.E., Rimmelzwaan G.F., Gruters R.A., and Osterhaus A.D. Vaccine-induced enhancement of viral infections. Vaccine 27 (2009) 505-512
12. Kliks S.C., Nisalak A., Brandt W.E., Wahl L., and Burke D.S. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 40 (1989) 444-451
13. Konishi E., and Fujii A. Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine. Vaccine 20 (2002) 1058-1067
14. Konishi E., Kosugi S., and Imoto J. Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine 24 (2006) 2200-2207
15. Kurane I., Mady B.J., and Ennis F.A. Antibody-dependent enhancement of dengue virus infection. Rev. Med. Virol. 1 (1991) 211-221
16. Libraty D.H., Endy T.P., Houng H.S., Green S., Kalayanarooj S., Suntayakorn S., Chansiriwongs W., Vaughn D.W., Nisalak A., Ennis F.A., and Rothman A.L. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J. Infect. Dis. 185 (2002) 1213-1221
17. Lindenbach B.D., Thiel H.-J., and Rice C.M. Flaviviridae: the viruses and their replication. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology. 5th ed. (2007), Lippincott Williams & Willkins Inc., Philadelphia 1101-1152
18. Lozzio C.B., and Lozzio B.B. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45 (1975) 321-334
19. Mehlhop E., Ansarah-Sobrinho C., Johnson S., Engle M., Fremont D.H., Pierson T.C., and Diamond M.S. Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe 2 (2007) 417-426
20. Morens D.M., Halstead S.B., and Marchette N.J. Profiles of antibody-dependent enhancement of dengue virus type 2 infection. Microb. Pathog. 3 (1987) 231-237
21. Nishioka K. Serum complement level in dengue hemorrhagic fever. Allerg. Immunol. 20-21 (1974-1975) 385-392
22. Pierson T.C., and Diamond M.S. Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev. Mol. Med. 10 (2008) e12
23. Roehrig J.T., Hombach J., and Barrett A.D. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol. 21 (2008) 123-132
24. Shaio M.F., Chang F.Y., and Hou S.C. Complement pathway activity in serum from patients with classical dengue fever. Trans. R. Soc. Trop. Med. Hyg. 86 (1992) 672-675
25. Stephenson J.R. Understanding dengue pathogenesis: implications for vaccine design. Bull. World Health Organ. 83 (2005) 308-314
26. Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S., Endy T.P., and Nisalak A. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 181 (2000) 2-9
27. Whitehead S.S., Blaney J.E., Durbin A.P., and Murphy B.R. Prospects for a dengue virus vaccine. Nat. Rev. Microbiol. 5 (2007) 518-528
28. Wu S.J., Grouard-Vogel G., Sun W., Mascola J.R., Brachtel E., Putvatana R., Louder M.K., Filgueira L., Marovich M.A., Wong H.K., Blauvelt A., Murphy G.S., Robb M.L., Innes B.L., Birx D.L., Hayes C.G., and Frankel S.S. Human skin Langerhans cells are targets of dengue virus infection. Nat. Med. 6 (2000) 816-820
29. Yamanaka A., Kosugi S., and Konishi E. Infection-enhancing and -neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels. J. Virol. 82 (2008) 927-937